$ELV
Price history, market instrument context, member research, and related headlines in one place.
ELV key statistics
NYSEUSD
52-week range
$274.8495%$436.24
Latest session $421.78–$433.77Elevance Health, Inc. (ELV) is a stock instrument quoted on NYSE in USD. The most recently published price is $428.09, up $2.82 (0.66%) from the previous close of $425.27. It has traded between $421.78 and $433.77 in the latest session. Over the past year it has ranged from $274.84 to $436.24, leaving it in the upper quarter of its 52-week range (95%). Reported volume for the session was 2.1M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Greenskeeper Asset Management, an independent firm that specializes in disciplined value investing, recently released its Q2 2026 scorecard. A copy is available to download here. After a slow start to the year, the Fund gained 10.9% in the quarter, lifting its year-to-date return to 1.9%. The rebound came as markets showed signs of rotating away from momentum […]
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its “Large Cap Strategy”. A copy of the letter is available to download here. The Strategy returned 3.42% net of fees, trailing the Russell 1000 Value Index’s 13.87% gain.
Investment management company Vulcan Value Partners recently released its second-quarter 2026 investor letter. A copy of the letter can be downloaded here. Vulcan Value Partners prioritizes long-term returns and lower risk over short-term performance.
Loading $ELV research…